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Introduction: TMEM106B is a transmembrane glycoprotein of unknown function located within endosome/
lysosome compartments expressed ubiquitously in various cell types. Previously, the genome-wide association study
(GWAS) identified a significant association of TMEM106B single nucleotide polymorphisms (SNPs) with development
of frontotemporal lobar degeneration with ubiquitinated TAR DNA-binding protein-43 (TDP-43)-positive inclusions
(FTLD-TDP), particularly in the patients exhibiting the progranulin (PGRN) gene (GRN) mutations. Recent studies
indicate that TMEM106B plays a pathological role in various neurodegenerative diseases, including Alzheimer’s
disease (AD). However, at present, the precise levels of TMEM106B expression in AD brains remain unknown.
Methods: By quantitative reverse transcription (RT)-PCR (qPCR), western blot and immunohistochemistry, we
studied TMEM106B and PGRN expression levels in a series of AD and control brains, including amyotrophic lateral
sclerosis, Parkinson’s disease, multiple system atrophy and non-neurological cases.
Results: In AD brains, TMEM106B mRNA and protein levels were significantly reduced, whereas PGRN mRNA levels
were elevated, compared with the levels in non-AD brains. In all brains, TMEM106B was expressed in the majority of
cortical neurons, hippocampal neurons, and some populations of oligodendrocytes, reactive astrocytes and
microglia with the location in the cytoplasm. In AD brains, surviving neurons expressed intense TMEM106B
immunoreactivity, while senile plaques, neurofibrillary tangles and the perivascular neuropil, almost devoid of
TMEM106B, intensely expressed PGRN.
Conclusions: We found an inverse relationship between TMEM106B (downregulation) and PGRN (upregulation)
expression levels in AD brains, suggesting a key role of TMEM106B in the pathological processes of AD.Introduction
Frontotemporal lobar degeneration (FTLD) provides the
second most common cause of presenile dementia world-
wide. The first international genome-wide association
study of FTLD with ubiquitinated TAR DNA-binding
protein-43-positive inclusions (FTLD-TDP) identified a
significant association with three distinct single nucleotide
polymorphisms (SNPs) numbered rs1020004, rs6966915,
and rs1990622 (top SNP) in the transmembrane protein
106B (TMEM106B) gene on chromosome 7p21.3 [1]. The
study also found that TMEM106B mRNA levels are
elevated by greater than 2.5-fold in the frontal cortex of
FTLD-TDP patients, compared with the levels of normal* Correspondence: satoj@my-pharm.ac.jp
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stated.subjects. The minor C allele on rs1990622 in the
TMEM106B gene confers significant protection against de-
velopment of FTLD, most notably in the patients with the
progranulin (PGRN) gene (GRN) mutations [1]. This asso-
ciation is replicated in independent cohorts [2,3]. A number
of previous studies showed that all GRN mutations cause
FTLD-TDP by the mechanism of haploinsufficiency due to
nonsense-mediated decay of mutated mRNAs [4,5]. A dif-
ferent study validated a substantial increase in TMEM106B
mRNA and protein levels in FLTD-TDP brains with GRN
mutations [6].
TMEM106B is a type II transmembrane glycoprotein of
unknown function located within the late endosome/lyso-
some compartments expressed ubiquitously in various cell
types, where the levels of TMEM106B expression are regu-
lated by lysosomal activities [7,8]. In rat neurons in culture,
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pleitropic functions involved in embryogenesis, oncogen-
esis, and inflammation, widely expressed in epithelial cells
of the skin, gastrointestinal tract and the reproductive
system, leukocytes, and neurons in the central nervous
system [10,11]. Sortilin, serving as a cell-surface receptor
for PGRN, regulates trafficking and targeting of PGRN to
lysosomes [12]. The risk T allele on rs1990622 in the
TMEM106B gene is linked to low plasma PGRN levels,
suggesting that TMEM106B SNPs modulate secreted levels
of PGRN [13,14]. A nonsynonymous SNP numbered
rs3173615 (p.T185S) located in exon 6 of the TMEM106B
gene shows complete linkage disequilibrium with rs1990622
[3,13,15]. The expression levels of the protective isoform
S185 are always lower than those of the risk isoform T185,
attributable to accelerated degradation of the S185 protein,
suggesting that increased expression of the T185 protein
might perturb the endolysosomal pathway [3]. Actually,
overexpression of TMEM106B induces enlargement of
lysosomes and inhibits lysosomal degradation of PGRN
[8]. Importantly, the frequency of carriers homozygous
for S185 on rs3173615 is reduced in the patients with
C9orf72 repeat expansions, the most common genetic
cause for FTLD [15], whereas the risk T allele on rs1990622
is positively associated with later age at onset and death in
C9orf72 repeat expansion carriers [16].
A recent study showed that TMEM106B genotypes
influence the development of cognitive impairment in
amyotrophic lateral sclerosis (ALS) patients [17]. The
risk T allele on rs1990622 in the TMEM106B gene is
significantly associated with poor cognitive performance
in ALS patients. Furthermore, the frequency of the pro-
tective C allele on rs1990622 is reduced in Alzheimer’s
disease (AD) cases presenting with TDP-43 pathology [18].
The interplay between TMEM106B and APOE genotypes
increases AD risk in a Han Chinese population [19]. All of
these observations suggest that TMEM106B plays a key
role in the pathology not only of FTLD-TDP but also of
other neurodegenerative diseases, such as AD. The precise
levels of TMEM106B expression in AD brains, however,
remain unknown at present. In the present study, we char-
acterized TMEM106B and PGRN expression levels in AD
and non-AD brains by quantitative reverse transcriptase-
polymerase chain reaction (qPCR), western blot and immu-
nohistochemistry. We found that the levels of TMEM106B
expression are substantially reduced, while those of PRGN
are elevated in AD brains.
Materials and methods
Human brain tissues
The serial sections of the frontal cortex and the hippocam-
pus were prepared from autopsied brains of six sporadic
AD patients, composed of three men and three women
with a mean age of 73 ± 9 years, and 13 non-AD patients,composed of six men and seven women with a mean age of
74 ± 8 years, as described previously [20]. The non-AD
group includes four normal subjects that died of non-
neurological causes (NC), three patients with sporadic Par-
kinson’s disease (PD), four patients with sporadic ALS, and
two patients with sporadic multiple system atrophy (MSA).
The demographic profile of the cases examined is presented
in Table 1. All AD cases met with the Consortium to Estab-
lish a Registry for Alzheimer’s Disease criteria for diagnosis
of definite AD [21]. They were categorized into stage C of
amyloid deposition and into stage VI of neurofibrillary de-
generation, following the Braak staging system [22]. Autop-
sies on all subjects were performed at the National Center
Hospital, National Center of Neurology and Psychiatry,
Japan or the Kohnodai Hospital, National Center for Global
Health and Medicine, Japan. In all cases, written informed
consent was obtained. The Ethics Committee of the Na-
tional Center of Neurology and Psychiatry for the Human
Brain Research, the Ethics Committee of the National Cen-
ter for Global Health and Medicine on the Research Use of
Human Samples, and the Human Research Ethics Commit-
tee of the Meiji Pharmaceutical University approved the
present study.
Immunohistochemistry
The brain tissues were fixed with 4% paraformaldehyde
and embedded in paraffin. After deparaffination, tissue
sections were heat-treated in 10 mM citrate sodium buf-
fer, pH 6.0, by autoclaving at 110°C for 15 minutes in a
temperature-controlled pressure chamber (Biocare Medical,
Concord, CA, USA). The sections were processed for
immunohistochemistry, according to the methods de-
scribed previously [23]. In brief, the tissue sections were in-
cubated at room temperature for 15 minutes with 3%
hydrogen peroxide-containing methanol to block the en-
dogenous peroxidase activity, and were also incubated with
phosphate-buffered saline containing 10% normal goat or
rabbit serum at room temperature for 15 minutes to block
nonspecific staining. The sections were then incubated at
4°C overnight with a rabbit polyclonal anti-TMEM106B
antibody raised against a peptide spanning amino acid resi-
dues 1 to 50 of the human TMEM106B protein at a con-
centration of 0.1 μg/ml (A303-439A; Bethyl Laboratories,
Montgomery, TX, USA), a rabbit monoclonal anti-PGRN
antibody raised against a synthetic peptide corresponding
to the residues in the human PGRN protein at a dilution of
1:1,000 (EPR3781; Abcam, Cambridge, UK), or a mouse
monoclonal anti-pS409/410 TDP-43 antibody raised against
a phosphopeptide composed of CMDSKpSpSGWGM at a
dilution of 1:500 (TIP-PTD-M01; Cosmo Bio, Tokyo,
Japan). The specificity of A303-439A and EPR3781
antibodies was validated individually by western blot ana-
lysis of the corresponding recombinant proteins expressed
in human cell lines in culture. After washing with
Table 1 Demographic profile of the cases examined in the present study
Case
number
















NC1 + + Acute myocardial infarction 1,130 1.4 A/II – – T/T
NC2 + + Acute myocardial infarction 1,350 1.6 0/II – – T/S
NC3 + + Lung cancer 1,060 3.9 A/II – – T/S
NC4 + + Dissecting aortic aneurysm 1,400 4.8 A/I – – T/T
AD1 + + Pneumonia 1,000 1.1 C/VI + + T/S
AD2 + Pneumonia 1,230 14 C/VI T/S
AD3 + + Pneumonia 1,220 10.5 C/VI – + T/S
AD4 + + Pneumonia 1,240 8.1 C/VI – – T/S
AD5 + + Lung cancer 1,090 4.5 C/VI – – T/T
AD6 + + Pulmonary infarction 840 3 C/VI – + T/S
AD7 + Respiratory failure
by aspiration
1,200 3.8 B/IV T/S
AD8 + Pneumonia 1,060 8 C/VI – +
PD1 + Pneumonia 1,330 9.5 B/IV S/S
PD2 + + Pneumonia 1,130 2.5 B/II – – T/S
PD3 + + Respiratory failure
by aspiration
910 2.5 B/II – – T/S
PD4 + Colon cancer 1,430 4 A/I S/S
PD5 + Pneumonia 1,320 9.3 C/III – –
ALS1 + + Respiratory failure 1,480 10.5 0/0 – – T/S
ALS2 + + Respiratory failure 1,090 1.3 0/I + + T/T
ALS3 + + Respiratory failure 1,560 3 0/I + + T/S
ALS4 + + Respiratory failure 1,320 10 0/II + – S/S
ALS5 + Respiratory failure 1,360 2.5 B/I T/S
ALS6 + Respiratory failure 1,600 13 B/I T/S
MSA1 + Pneumonia, septicemia 1,040 1.5 0/I – –
MSA2 + Pneumonia 1,090 12 A/I – –
The demographic profile of the cases processed for immunohistochemistry (IHC), quantitative reverse transcriptase-polymerase chain reaction (qPCR), and western blotting
(WB) is shown with the case number, the cause of death, brain weight, the postmortem interval, the Braak staging (amyloid deposition/neurofibrillary degeneration),
phosphorylated TAR DNA-binding protein-43 (pTDP-43) immunoreactivity in the frontal cortex and the hippocampus, and the p.T185S genotype of the rs3173615 single
nucleotide polymorphism. AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; MSA, multiple system atrophy; NC, non-neurological causes; PD, Parkinson’s disease.
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at room temperature for 30 minutes with peroxidase-
conjugated secondary antibodies (Nichirei, Tokyo, Japan),
followed by incubation with diaminobenzidine tetrahydro-
chloride substrate (Vector, Burlingame, CA, USA). The sec-
tions were processed for a counterstain with hematoxylin.
For negative controls, the primary antibody was omitted
from the reaction.
Reverse transcriptase-polymerase chain reaction analysis
The source of human neural cell lines processed for re-
verse transcriptase-polymerase chain reaction (PCR)
was described elsewhere. Total cellular RNA was extractedusing TRIZOL (Invitrogen, Carlsbad, CA, USA). RNA
treated with DNase I was processed for cDNA synthesis
using oligo(dT)20 primers and SuperScript II reverse tran-
scriptase (Invitrogen). cDNA was then amplified by PCR
using HotStar Taq DNA polymerase (Qiagen, Valencia, CA,
USA) and a panel of sense and antisense primer sets as
follows: 5′-ctgacctgttcatacctgagccat-3′ and 5′-tgggagat
atagaccagggttgca-3′ for a 168 base pair (bp) product of
the human TMEM106A gene (NCBI Reference Sequence
Number NM_145041); 5′-aggaagaattcctagggggcaaga-3′ and
5′-atttcacgtcgatagagcgaggga-3′ for a 173 bp product of the
human TMEM106B gene (NM_018374); 5′-cgtgatttcccac
agttccatgag-3′ and 5′-aagtacgtgatcttcagccagtcc-3′ for a
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TMEM106B gene (NM_018374); 5′-atacattggcctcatgaccc
agag-3′ and 5′-cttgggaacatatgctgtgctctc-3′ for a 140 bp
product of the human TMEM106C gene (NM_024056);
5′-tgagggacagtactgaagactctg-3′ and 5′-tctgacagggaaggcctt
agattg-3′ for a 167 bp product of the human GRN gene
(NM_002087); 5′-atgaggaggaaggagagaagggga-3′ and
5′-ccttccctttcctgtctgagtctc-3′ for a 188 bp product of
the human glial fibrillary acidic protein (GFAP) gene
(NM_002055); 5′-gagaaaggaacatccggaacagcc-3′ and 5′-
tgggagtgccctctcttgctaaca-3′ for a 180 bp product of the
human neurofilament, heavy polypeptide (NFH) gene
(NM_021076); 5′-tacggagcggtcgtgtatcaggat-3′ and 5′-agctgc
gtagactctgccgtaact-3′ for a 132 bp product of the
human RNA binding protein, fox-1 homolog (Caenor-
habditis elegans)-3 (RBFOX3, also named NEUN) gene
(NM_001082575); and 5′-ccatgttcgtcatgggtgtgaacca-3′ and
5′-gccagtagaggcagggatgatgttc-3′ for a 251 bp product of the
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene
(NM_002046).
For qPCR, cDNA prepared from frozen human brain
tissues and a reference RNA of the human frontal cortex
(AM6810; Invitrogen/Ambion) was amplified by PCR in a
LightCycler ST300 (Roche Diagnostics, Tokyo, Japan) using
SYBR Green I and the primer sets described above. The ex-
pression levels of target genes were standardized against
the levels of G3PDH detected in the corresponding cDNA
samples. All assays were performed in triplicate.
p.T185S genotyping
The rs3173615 SNP composed of p.T185S (C760G) in exon
6 of the human TMEM106B gene was studied by direct se-
quencing of a 226 bp product amplified from brain cDNA
by PCR using a primer set of 5′-cagcctatgtcagttatgatg-3′
and 5′-tctgctataacggtaggtact-3′. The representative data are
shown in Figure S1a,b,c in Additional file 1.
Vector construction
To study the specificity of anti-TMEM106B antibody,
the full-length open reading frame of the human
TMEM106A gene, the human TMEM106B gene, the hu-
man TMEM106C gene, or the human GRN gene was amp-
lified by PCR using PfuTurbo DNA polymerase (Agilent
Technologies, Palo Alto, CA, USA) and the set of sense
and antisense primers. Subsequently, PCR products were
cloned in the expression vector pcDNA4/HisMax-TOPO
(Invitrogen) to express a fusion protein with an N-terminal
Xpress tag. The vectors were transfected in HeLa cells, SK-
N-SH cells, or HEK293 cells using Lipofectamine 2000 re-
agent (Invitrogen) for transient expression.
Western blot analysis
To prepare total protein extract, cultured cells and fro-
zen brain tissues were homogenized in RIPA buffer(Sigma, St. Louis, MO, USA), NP-40 lysis buffer (home-
made), or buffer containing 8 M urea, 2% CHAPS, 0.5%
carrier ampholytes pH 4 to 7, 20 mM dithiothreitol supple-
mented with a cocktail of protease inhibitors (Sigma) – this
homogenization was then followed by centrifugation at
12,000 rpm for 10 minutes at room temperature to harvest
the supernatant. The protein was separated on 12%
SDS-PAGE gel. After gel electrophoresis, the protein was
transferred onto nitrocellulose membranes, followed by
incubation at room temperature overnight with the
anti-TMEM106B antibody A303-439A, rabbit polyclonal
anti-TMEM106B antibody raised against a peptide spanning
amino acid residues 101 to 200 of the human TMEM106B
protein (bs-11694R; Bioss, Boston, MA, USA), rabbit poly-
clonal anti-TMEM106B antibody raised against the human
TMEM106B-GST fusion protein (20995-1-AP; Proteintech,
Chicago, IL, USA), or mouse monoclonal anti-Xpress anti-
body (Invitrogen). The membranes were then incubated at
room temperature for 30 minutes with horseradish peroxid-
ase-conjugated anti-rabbit IgG (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The specific reaction was visualized
by exposing them to a chemiluminescent substrate (Pierce,
Rockford, IL, USA). After the antibodies were stripped by
incubating the membranes at 50°C for 30 minutes in strip-
ping buffer, composed of 62.5 mM Tris–HCl, pH 6.7, 2%
SDS, and 100 mM 2-mercaptoethanol, the membranes were
processed for relabeling with anti-heat shock protein HSP60
antibody (sc-1052; Santa Cruz Biotechnology), serving as an
internal control of protein loading. The signal intensity of
TMEM106B-immunoreactive bands was quantified using
ImageJ software (National Institute of Health, Bethesda,
MD, USA), and the expression levels were standardized in-
dividually by the corresponding HSP60 signal intensity.
Statistical analysis
The statistical significant difference between two groups
was evaluated by Student’s t test. A significant difference
among >2 groups was evaluated by one-way analysis of
variance followed by Turkey’s post hoc test. The differ-
ences in the frequency of T185 and S185 isoforms be-
tween the groups were evaluated after allocating score 0
to the T185 allele and score 1 to the S185 allele. The
correlation between two groups was evaluated by Pearson’s
correlation coefficient test. P < 0.05 in the two-tailed test
was considered significant.
Results
Evolutional conservation of TMEM106B
Multiple sequence alignment analysis revealed that the
TMEM106B gene is highly conserved in various vertebrates
through evolution. The amino acid sequence of the human
TMEM106B protein was 100%, 96%, 95%, 96%, 95%,
87%, 75%, and 68% identical to the sequences of orthologs
derived from Pan troglodytes, Canis lupus familiaris, Bos
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Danio rerio, and Xenopus laevis, respectively (Figure 1a).
Furthermore, the amino acid sequence of the human
TMEM106B protein was 49% and 47% identical to the
sequences of the human TMEM106A and TMEM106C
proteins, respectively (Figure 1b), suggesting that the
latter two represent paralogues of TMEM106B.
Universal expression of TMEM106A, TMEM106B,
TMEM106C, and PGRN mRNAs in human neural cells
By reverse transcriptase-PCR, all cells and tissues
examined – including the human cerebrum, astrocytes,
neuronal progenitor cells, NTera2 teratocarcinoma-derived
neurons, SK-N-SH neuroblastoma, IMR-32 neuroblastoma,
U-373MG glioblastoma, T98 glioblastoma, and HMO6
immortalized microglia – expressed varying levels of
TMEM106A, TMEM106B, TMEM106C, and PGRNFigure 1 Multiple sequence alignment of TMEM106B protein. Multiple
corresponding amino acid sequences into CLC Free Workbench (CLC Bio/Q
of TMEM106B orthologs derived from Homo sapiens, Pan troglodytes, Canis
Danio rerio, and Xenopus laevis. (b) Multiple amino acid sequence alignmentranscripts (Figure 2a,b,c,d, lanes 1,3 to 10). The levels
of G3PDH, a housekeeping gene, were almost constant in
the cells and tissues examined (Figure 2e, lanes 1,3 to 10).
No products were amplified when the reverse transcription
step is omitted (Figure 2a,b,c,d,e, lane 2). The expression
of TMEM106A, TMEM106B, TMEM106C, and PGRN
mRNAs is thus universal in human neural cell lines.
Reduced expression of TMEM106B mRNA in Alzheimer’s
disease brains
We next analyzed by qPCR the levels of TMEM106B,
PGRN, and G3PDH mRNAs in frozen human brain tissues
derived from four NC cases, six ALS cases, four PD cases,
and seven AD cases presented in Table 1. Before starting
this, we investigated the p.T185S genotype of rs3173615 in
the human TMEM106B gene, on which the T185 iso-
form acts as a risk factor, while the S185 isoform servesamino acid sequence alignment was performed by importing the
iagen, Aarhus, Denmark). (a) Multiple amino acid sequence alignment
lupus familiaris, Bos Taurus, Mus musclus, Rattus norvegicus, Gallus gallus,














































Figure 2 Universal expression of TMEM106B mRNAs in human
neural cells. mRNA expression was studied by reverse transcriptase
(RT)-polymerase chain reaction (PCR) in human tissues and cultured
cells. (a) TMEM106A, (b) TMEM106B, (c) TMEM106C, (d) progranulin
(PGRN), and (e) G3PDH, a housekeeping gene for a positive control.
The lanes indicate (1) the frontal cortex of the human cerebrum
(CBR) with inclusion of the RT step, (2) CBR without inclusion of the
RT step, (3) astrocytes (AS), (4) neuronal progenitor (NP) cells, (5)
NTera2 teratocarcinoma-derived neurons, (6) SK-N-SH neuroblastoma,
(7) IMR-32 neuroblastoma, (8) U-373MG glioblastoma, (9) T98G
glioblastoma, and (10) HMO6 microglia. TMEM106A, TMEM106B,
TMEM106C, and PGRN were amplified for 35 cycles, while G3PDH was
amplified for 28 cycles.
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mutations. In the brains examined, the T185/T185 homo-
zygote consisted of four cases (19.0%), the T185/S185
heterozygote consisted of 14 cases (66.7%), and the S185/
S185 homozygote consisted of three cases (14.3%) (Table 1),
consistent with the genotyping data of HapMap-JPT
[24]. The frequency of T185 and S185 isoforms was thus
not significantly different between AD and non-AD groups
(P = 0.6134).
By qPCR, AD cases showed significantly reduced mRNA
levels of TMEM106B, when compared with those in non-
AD cases (P = 0.0035) (Figure 3a,c). In contrast, AD cases
showed significantly elevated mRNA levels of PGRN, with
some variations among the cases, when compared with the
levels in non-AD cases (P = 0.0027) (Figure 3b,d). Not-
ably, a significant negative correlation was found between
TMEM106B and PGRN mRNA expression levels (Pearson’s
correlation coefficient = −0.555; P = 0.0090) (Figure 3e).
Furthermore, AD cases showed significantly reduced mRNA
levels of NFH and elevated mRNA levels of GFAP and
NEUN, when compared with the levels in non-AD cases
(P = 0.0003 for NFH, P = 0.0004 for GFAP, and P = 0.0156
for NEUN) (Figure 4a,b,c). Importantly, a significant
positive correlation was found between TMEM106B andNFH mRNA expression levels (Pearson’s correlation
coefficient = 0.496; P = 0.0221) (Figure 4d).
Moreover, we studied by qPCR the levels of TMEM106A
and TMEM106C mRNAs in AD and non-AD brains. Both
were markedly elevated in AD brains, compared with
the levels in non-AD brains (P = 0.0002 for TMEM106A
and P = 0.0005 for TMEM106C) (Figure S2a,b,c,d in
Additional file 2). The expression of TMEM106B paralo-
gues was uniquely regulated in the opposite direction to
the expression levels of TMEM106B.
Characterization of the specificity of anti-TMEM106B antibody
The specificity of anti-human TMEM106 antibody was veri-
fied by western blot of recombinant human TMEM106A,
TMEM106B, and TMEM106C proteins tagged with Xpress
expressed in HeLa cells. The A303-439A anti-TMEM106B
antibody recognized 45 kDa monomeric and 120 kDa oligo-
meric forms of TMEM106B tagged with Xpress (Figure 5a,
b, lane 3), whereas it did react either with TMEM106A or
with TMEM106C (Figure 5a,b, lanes 2 and 4), validating the
specificity of the A303-439A antibody. In contrast, both bs-
11694R and 20995-1-AP anti-TMEM106B antibodies did
not specifically react with the Xpress-tagged human
TMEM106B protein (data not shown). We therefore se-
lected A303-439A for western blot and immunohistochem-
istry analysis in the present study. This antibody specifically
reacted with a major 31 kDa protein endogenously
expressed in human brain tissues and IMR-32 neuroblast-
oma cells (Figure 5d, lanes 5 to 7).
Reduced expression of TMEM106B protein in Alzheimer’s
disease brains
Next, we quantitatively analyzed the levels of TMEM106B,
PGRN, and HSP60 proteins in frozen human brain tissues
derived from four NC cases, six ALS cases, four PD cases,
and seven AD cases, presented in Table 1, by western blot
using the A303-439A antibody. AD cases showed signifi-
cantly reduced levels of TMEM106B, when compared
with the levels in non-AD cases (P = 0.0000004)
(Figure 6Aa,C). AD cases showed a trend for elevated ex-
pression levels of PRGN when compared with the levels in
non-AD cases, but the difference did not reach statistical
significance (P = 0.5304) (Figure 6Ba,D). We found no dis-
cernible correlation between TMEM106B and PRGN
protein expression levels (Pearson’s correlation coeffi-
cient = −0.242; P = 0.2912) (Figure 6E).
Immunohistochemical analysis of TMEM106B expression
in Alzheimer’s disease and non-Alzheimer’s disease brains
We next studied the expression of TMEM106B in the
frontal cortex and the hippocampus of six AD cases and
13 non-AD cases, composed of four NC cases, four ALS
cases, three PD cases, and two MSA cases, presented in






Figure 3 Reduced expression of TMEM106B mRNA in Alzheimer’s disease brains. TMEM106B and progranulin (PGRN) mRNA expression
levels were studied by quantitative reverse transcriptase-polymerase chain reaction (qPCR) in human brain tissues derived from a reference of the
human frontal cortex (REF), four non-neurological control cases (NC), six amyotrophic lateral sclerosis (ALS) cases, four Parkinson’s disease (PD)
cases, and seven Alzheimer’s disease (AD) cases. The expression levels were standardized against those of G3PDH. (a) TMEM106B mRNA expression.
(b) PGRN mRNA expression. (c) Difference in TMEM106B levels between AD and non-AD cases. *P = 0.0035 by Student’s t test. (d) Difference in PGRN
levels between AD and non-AD cases. **P = 0.0027 by Student’s t test. (e) Pearson’s correlation between TMEM106B and PGRN mRNA levels. Pearson’s
correlation coefficient indicates −0.555 (P = 0.0090).
Satoh et al. Alzheimer's Research & Therapy 2014, 6:17 Page 7 of 14
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ology in the brains examined. Among 19 cases, four AD
cases and three ALS cases – but no cases of NC, PD, or
MSA – showed neuronal or glial pTDP-43 immunoreac-
tivity in the frontal cortex and/or the hippocampus (Table 1;
Figure S3a,b,c,d in Additional file 3). In all cases examined,
TMEM106B was expressed in the majority of cortical neu-
rons, hippocampal pyramidal neurons and dentate gyrus
granule cells, located in the cytoplasm by forming fine
granular structures, particularly enriched in the soma and
in proximal neurites (Figure 7a,b,c,d). TMEM106B immu-
noreactivity was occasionally concentrated in the peri-
nuclear region by forming small nodular structures in some
populations of hippocampal pyramidal neurons (Figure 7e).
Furthermore, subpopulations of oligodendrocytes, reactive
astrocytes, and microglia expressed TMEM106B intensely,
located in the cytoplasm (Figure 7f; Figure S4b,c inAdditional file 4). Neuronal cytoplasmic TMEM106B im-
munoreactivity was greatly reduced after absorption of the
antibody by extract of the Xpress-tagged TMEM106B pro-
tein (Figure S4e,f in Additional file 4).
In AD brains, cortical neurons and hippocampal pyram-
idal neurons were greatly reduced in number, along with
substantial reduction of TMEM106B-expressing neurons.
However, surviving neurons in AD brains moderately or
intensely expressed TMEM106B immunoreactivity in the
cytoplasm (Figure 8a,c). Senile plaques were most often
unlabeled and rarely faintly labeled by the A303-439A anti-
body (Figure 8a,e). In contrast, senile plaques, neurofibril-
lary tangles, and the perivascular neuropil were frequently
and intensely labeled with anti-PGRN antibody EPR3781
(Figure 8b,d,f). Some populations of activated microglia
also expressed PGRN (Figure S4d in Additional file 4).
The vacuoles of granulovacuolar degeneration (GVD)
Figure 4 Positive correlation between TMEM106B and neurofilament, heavy polypeptide mRNA levels. Neurofilament, heavy polypeptide
(NFH), glial fibrillary acidic protein (GFAP), and RNA-binding protein, fox-1 homolog (Caenorhabditis elegans)-3 (RBFOX3, NEUN) mRNA expression
levels were studied by quantitative reverse transcriptase-polymerase chain reaction (qPCR) in human brain tissues derived from a reference of the
human frontal cortex (REF), four non-neurological causes (NC) cases, six amyotrophic lateral sclerosis (ALS) cases, four Parkinson’s disease PD cases,
and seven AD cases. The expression levels were standardized against those of G3PDH. (a) NFH expression. (b) GFAP expression. (c) NEUN expression.
(d) Pearson’s correlation between TMEM106B and NFH mRNA levels. Pearson’s correlation coefficient indicates 0.496 (P = 0.0221).
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CA1 region were devoid of TMEM106B immunoreactivity
(Figure S4a in Additional file 4).
Overexpression of TMEM106B and PGRN did not alter
their mRNA expression levels
Finally, we studied by qPCR the direct inverse relationship
between TMEM106B and PGRN mRNA expression in
SK-N-SH neuroblastoma cells following overexpression
of Xpress-tagged TMEM106B, PGRN, and LacZ proteins
(Figure S5a, lanes 2 to 4 in Additional file 5). Transient
overexpression of the TMEM106B, PGRN, or LacZ
transgene did not significantly alter the levels of en-
dogenous TMEM106B and PGRN mRNAs (P = 0.4726
for TMEM106B and P = 0.1204 for PGRN) (Figure S5c,d in
Additional file 5). These results suggest that TMEM106B is
not directly involved in transcriptional regulation of the
GRN gene, and vice versa.Discussion
By multiple sequence alignment analysis, we found that
the TMEM106B gene is highly conserved in various
vertebrates through evolution, and it shows substantial
homology to both TMEM106A and TMEM106C genes
that represent TMEM106B paralogues. Recent studies
indicate that TMEM106B plays a pathological role in a
wide range of neurodegenerative diseases [17-19,25]. By
qPCR, western blot and immunohistochemistry, we studied
TMEM106B and PGRN expression levels in a series of AD
and non-AD brains. We found that TMEM106B mRNA
and protein levels are significantly reduced in AD brains,
while PGRN mRNA levels were elevated in AD brains,
compared with the levels in non-AD brains. In all brains
examined, TMEM106B was expressed in the majority
of cortical neurons, hippocampal neurons, and subpopula-
tions of oligodendrocytes, reactive astrocytes, and micro-
glia. These observations largely agree with a recent report

























Figure 5 Characterization of anti-TMEM106B antibody. The full-length open reading frame (ORF) cloned in the vector that expresses a fusion
protein with an N-terminal Xpress tag was transiently expressed in HeLa cells. Total protein extract was processed for western blot. Lanes represent the
protein of (1) untransfected cells and the cells expressing (2) TMEM106A, (3) TMEM106B, or (4) TMEM106C, and the protein of (5) human brain
#1, (6) human brain #2, or (7) IMR-32 neuroblastoma cells. Immunoblots of (a, d) TMEM106B (the A303-439A antibody), (b) Xpress, and (c, e)
HSP60, an internal control for protein loading.
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human brains [26]. Although cortical neurons were most
evidently lost in AD brains at advanced stages compared
with non-AD brains, surviving neurons expressed fairly in-
tense TMEM106B immunoreactivity, suggesting the possi-
bility that reduced expression of TMEM106B in AD brains
might simply reflect greater loss of neurons in the cerebral
cortex. In contrast, senile plaques, neurofibrillary tangles,
and the perivascular neuropil expressed intense PGRN im-
munoreactivity. These observations are well consistent with
previous studies showing enhanced expression of PGRN in
microglia, neurons, and neurites surrounding amyloid pla-
ques in AD brains [4,10,27]. Importantly, we found that AD
cases show significantly reduced mRNA levels of NFH
and elevated mRNA levels of GFAP, when compared
with the levels in non-AD cases, reflecting enhanced
neuronal loss and astrogliosis in AD brains. Furthermore,
we identified a discernible positive correlation between
TMEM106B and NFH mRNA expression levels. Unex-
pectedly, we found a significant elevation in NEUN
mRNA levels, a nuclear marker specific for subpopulations
of neurons, in AD brains.
The rs1990622 SNP in the TMEM106B gene, being in
complete linkage disequilibrium with the coding rs3173615
SNP of p.T185S, is closely associated with FTLD-TDP in
the patients with GRN mutations, who are characterized
by lower plasma PGRN levels [3,25]. Previous studies alsoshowed that TMEM106B mRNA and protein levels are
elevated in FLTD-TDP brains with GRN mutations
[1,6]. The expression levels of the risk isoform T185
are much higher than those of the protective isoform
S185 owing to destabilization of the S185 protein [3].
Overexpression of TMEM106B inhibits lysosomal function,
thereby leading to disturbed turnover of PGRN [8]. An
inverse relationship has thus been established in the
expression levels between TMEM106B (upregulation)
and PGRN (downregulation) in FTLD-TDP. PGRN acts as
a pivotal neuronal survival factor, potentially deficient
in the brains of neurodegenerative diseases [10,11]. All
of these observations suggest that deficient expression of
PGRN triggered by elevated expression of TMEM106B
promotes neurodegeneration. However, in contrast to
FLTD-TDP brains with GRN mutations, we found that
TMEM106B mRNA and protein levels are reduced in AD
brains. In the present study, the frequency of T185 and
S185 isoforms was not significantly different between
AD and non-AD cases. As a result, we unexpectedly
found a reverse inverse correlation between TMEM106B
(downregulation) and PGRN (upregulation) in AD brains at
least at mRNA expression levels. The possible scenario that
TMEM106B plays a protective role against the neurodegen-
erative processes in AD could therefore be raised, although
further studies on in vitro and in vivo TEME106B knock-







Figure 6 Reduced expression of TMEM106B protein in Alzheimer’s disease brains. Protein expression levels were studied by western blot
in human brain tissues derived from four non-neurological causes (NC) cases, six amyotrophic lateral sclerosis (ALS) cases, four Parkinson’s disease
(PD) cases, and seven Alzheimer’s disease (AD) cases. The expression levels were standardized against those of HSP60. (A) TMEM106B expression:
(a) TMEM106B and (b) HSP60. (B) Progranulin (PGRN) expression: (a) PGRN and (b) HSP60. (C) Difference in TMEM106B levels between AD and
non-AD cases. *P = 0.0000004 by Student’s t test. (D) Difference in PGRN levels between AD and non-AD cases. ns, non-significant (P = 0.5304 by
Student’s t test). (E) Pearson’s correlation between TMEM106B and PGRN protein levels. Pearson’s correlation coefficient indicates −0.242 (P = 0.2912).
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elevated mRNA levels of PGRN, when compared with
the levels in non-AD cases. However, we did not find a
significant elevation of PGRN protein levels in AD
brains, leading to no obvious inverse correlation between
TMEM106B and PGRN protein expression levels. The
inconsistency between PGRN mRNA and protein levels
is attributable to the complex post-transcriptional modifi-
cation of the PGRN protein. The PGRN protein contains
7.5 tandem repeats of 12 cysteinyl motifs separated by
linkers. When secreted extracellularly, PGRN – cleaved
by elastase and matrix metalloproteases within linker
regions – generates several smaller fragments called
granulins (GRNs), composed of GRN A to G and para-
granulin or epithelins.
Importantly, the full-length PRGN and its cleaved
fragment GRNs play a discrete role in regulation of various
biological responses [10,11]. PGRN exhibits neurotrophicand anti-inflammatory activities, whereas GRNs serve as a
proinflammatory mediator. Expression levels of PGRN,
whose release is facilitated by anti-inflammatory stimuli in
microglia, are elevated in multiple sclerosis brains [28,29].
Astrocytes produce large amounts of secretory leukocyte
protease inhibitor, a negative regulator of proteolytic
processing of PGRN, in response to proinflammatory
stimuli [28]. In contrast, PGRN acts as a chemotactic
factor for microglia capable of producing large amounts
of reactive oxygen species, although microglia, following
exposure to PGRN, show an enhanced capacity to phago-
cytose amyloid-β1-42 [30]. At present, therefore, whether
upregulated expression of PGRN in AD brains plays a
neuroprotective or neurotoxic role remains unknown.
We found that overexpression of either TMEM106B or
PGRN transgene in SK-N-SH neuroblastoma cells does
not immediately affect endogenous levels of PGRN or





Figure 7 TMEM106B immunoreactivity in non-Alzheimer’s disease brains. Expression of TMEM106 immunoreactivity was studied in 13
non-Alzheimer’s disease brains presented in Table 1 by immunohistochemistry using the A303-439A antibody. (a) Non-neurological causes (NC),
the frontal cortex, cytoplasmic staining of cortical neurons; (b) amyotrophic lateral sclerosis (ALS), the frontal cortex, cytoplasmic staining of cortical
neurons; (c) NC, the hippocampal CA1 region, cytoplasmic staining of pyramidal neurons; (d) ALS, the hippocampal CA1 region, cytoplasmic staining
of pyramidal neurons; (e) NC, the hippocampal CA1 region, intense staining of small nodular structures accumulated in the perinuclear region of
pyramidal neurons; (f) NC, the frontal white matter, cytoplasmic staining of oligodendrocytes, reactive astrocytes, and microglia.
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It is worthy of note that TMEM106B is co-localized
with PGRN within the endosome/lysosome compartments
[3], and treatment with inhibitors of lysosomal acidification,
such as bafilomycin A1, ammonium chloride, and chloro-
quine, elevates TMEM106B levels in mouse neural cells [8].
A recent study found that the frequency of the protective
C allele on rs1990622 in the TMEM106B gene, show-
ing the complete linkage disequilibrium with p.T185S
on rs3173615 [3,13,15], is reduced in AD cases exhibiting
TDP-43 pathology [18]. In contrast, we found no difference
in the frequency of T185 and S185 isoforms on rs3173615
between AD and non-AD cases. TDP-43, a nuclear RNA/
DNA-binding protein capable of interacting with UG/TG
repeat stretches of target RNAs/DNAs, plays a key role in
regulation of transcription, alternative splicing, mRNA sta-
bility and transport, and microRNA biogenesis, actively
involved in the pathogenesis of FTLD/ALS termed TDP-
43 proteinopathy [31]. Because TMEM106B is identified
as a direct target for TDP-43-regulated gene expression
[32], the cytoplasmic sequestration of TDP-43 in TDP-43proteinopathy might induce deregulated expression of
TMEM106B in neurons containing TDP-43-positive
inclusions. In the present study, four out of six AD
cases showed TDP-43 pathology in the frontal cortex
and/or the hippocampus. Among these we found that
three cases (AD1, AD3, and AD6) show markedly re-
duced TMEM106B mRNA and protein expression levels
(see Figures 3a, 6A), suggesting an involvement of aber-
rant regulation of the TMEM106B gene by TDP-43 in
the pathogenesis of AD, although larger cohorts are re-
quired to evaluate this possibility.
In contrast to downregulation of TMEM106B expres-
sion, the expression of two paralogues of TMEM106B
(TMEM106A and TMEM106C) was markedly upregulated
at mRNA levels, almost specifically expressed in AD brains.
The corresponding genes are located in different chro-
mosomes – that is, TMEM106A (17q21.31), TMEM106B
(7p21.3), and TMEM106C (12q13.1) – whose expression
is presumably regulated by distinct mechanisms. The pos-
sibility exists that upregulation of the functionally relevant





Figure 8 TMEM106B and PGRN immunoreactivities in Alzheimer’s disease brains. Expression of TMEM106 and progranulin (PGRN)
immunoreactivities was studied in six Alzheimer’s disease brains presented in Table 1 by immunohistochemistry using the A303-439A antibody.
(a) TMEM106B, the frontal cortex, moderate neuronal cytoplasmic staining and faint senile plaque staining; (b) PGRN, same region as (a),
moderate senile plaque staining and diffuse neuropil staining; (c) TMEM106B, the hippocampal CA1 region, intense neuronal and astroglial cytoplasmic
staining; (d) PGRN, same region as (c), intense perivascular neuropil staining; (e) TMEM106B, the hippocampal CA1 region, no staining of senile plaques
and neurofibrillary tangles; (f) PGRN, same region as (e), moderate staining of numerous senile plaques and neurofibrillary tangles.
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to evaluate this possibility.
In AD brains, granulovaculoar degeneration bodies,
a kind of autophagosome, express immunoreactivity for
charged multivesicular body protein 2B (CHMP2B), whose
genetic mutations definitely cause FTLD [33]. We found
that granulovacuolar degeneration vacuoles (GVD) located
in hippocampal CA1 pyramidal neurons of AD brains
are devoid of TMEM106B immunoreacitivity. At present,
the mechanisms responsible for reduced expression of
TMEM106B in AD brains remain unknown. If downregu-
lation of TMEM106B is directly or indirectly involved in
neurodegeneration, we could propose the hypothesis that
TMEM106B plays a protective role against the neurodegen-
erative processes in AD. Worthy of note is that by analyzing
the promoter region of the TMEM106B gene with bioinfor-
matics tools for the Database of Transcriptional Start
Site [34] and the Matrix Search for Transcription Factor
Binding Sites [35], we identified three potential binding
sites for POU class 2 homeobox 1 (POU2F1; OCT1), a
transcription factor of the POU transcription factor family(unpublished observations) whose SNP is closely associated
with the genetic risk of AD [36].
Conclusions
TMEM106B mRNA and protein expression levels were
reduced, while PGRN mRNA levels were elevated, in
AD brains compared with the levels in non-AD brains.
TMEM106B was expressed in the cytoplasm of cortical
neurons, hippocampal neurons, and subpopulations of
oligodendrocytes, reactive astrocytes, and microglia.
In AD brains, surviving neurons expressed moderate/intense
TMEM106B immunoreactivity, while senile plaques, neuro-
fibrillary tangles, and the perivascular neuropil intensely
expressed PGRN. These observations suggest an active role
of TMEM106B in the pathological processes of AD.
Additional files
Additional file 1: Figure S1. Showing p.T185S genotyping analysis. The
rs3173615 SNP composed of p.T185S (C760G) in exon 6 of the human
TMEM106B gene was studied by direct sequencing of PCR product
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http://alzres.com/content/6/2/17amplified from brain cDNA. (a) T185/T185 homozygote, (b) T185/S185
heterozygote, and (c) S185/S185 homozygote.
Additional file 2: Figure S2. Showing elevated expression of
TMEM106A and TMEM106C mRNA in AD brains. The TMEM106A and
TMEM106C mRNA expression levels were studied by qPCR in human
brain tissues derived from a REF, four NC cases, six ALS cases, four PD
cases, and seven AD cases. The expression levels were standardized
against those of G3PDH. (a) TMEM106A. (b) TMEM106C. (c) Difference in
TMEM106A levels between AD and non-AD cases. *P = 0.0002 by
Student’s t test. (d) Difference in TMEM106C levels between AD and
non-AD cases. **P = 0.0005 by Student’s t test.
Additional file 3: Figure S3. Showing pTDP-43 immunoreactivity in AD
and non-AD brains. The expression of phosphorylated TDP-43 (pTDP-43)
immunoreactivity was studied in six AD brains and 13 non-AD brains
presented in Table 1 by immunohistochemistry using anti-pS409/410
TDP-43 antibody. (a) AD, the hippocampal granule cell layer, neuronal
cytoplasmic staining; (b) ALS, the hippocampal granule cell layer, neuronal
cytoplasmic staining; (c) AD, the frontal cortex, microglial cytoplasmic
staining; (d) ALS, the frontal cortex, neuronal cytoplasmic staining.
Additional file 4: Figure S4. Showing TMEM106B and PGRN
immunoreactivities in AD and non-AD brains. The expression of TMEM106
and PGRN immunoreactivities was studied in six AD brains and 13
non-AD brains presented in Table 1 by immunohistochemistry using the
A303-439A antibody. (a) TMEM106B, AD, the hippocampal CA1 region,
vacuoles of granulovacuolar degeneration (GVD) devoid of staining;
(b) TMEM106B, AD, the hippocampal molecular layer, intense astroglial
cytoplasmic staining; (c) TMEM106B, AD, the periventricular white matter,
intense oligodendroglial cytoplasmic staining; (d) PGRN, AD, the frontal
white matter, intense microglial cytoplasmic staining; (e) TMEM106B,
PD, the frontal cortex, moderate/intense neuronal cytoplasmic staining;
(f) TMEM106B after absorption of the antibody, same region as (e),
diminished neuronal cytoplasmic staining.
Additional file 5: Figure S5. Showing overexpression of TMEM106B or
PGRN did not alter PGRN or TMEM106B mRNA expression levels in
SK-N-SH neuroblastoma cells. SK-N-SH neuroblastoma cells expressing
Xpress-tagged recombinant proteins were processed for western blot and
qPCR. Immunoblot of (a) Xpress and (b) HSP60, an internal control for
protein loading. Lanes represent the protein of (1) untransfected cells and
the cells expressing (2) TMEM106B, (3) PGRN, and (4) LacZ tagged with
Xpress. mRNA expression levels of (c) TMEM106B and (d) PGRN in SK-N-SH
cells exposed to Lipofectamine 2000 alone (CNT) and following expression
of TMEM106B, PGRN, and LacZ proteins tagged with Xpress. (Single star
indicates P = 0.1204 by one-way ANOVA, while double star indicates
P = 0.4726 by one-way ANOVA).Abbreviations
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